Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.

ABSTRACT:

Rationale

BRAF and MEK inhibitors (BRAF/MEKi) are targeted therapy for proto-oncogene BRAF mutated metastatic unresectable melanoma. Compared to monotherapy, an increased cardiovascular toxicity is reported with the combination of Dabrafenib and Trametinib. This case report documents Grade 4 cardiac treatment emergent adverse effect of pericardial effusion and cardiac tamponade induced by this combination therapy.

Patient concerns

A 52 year old man presented with clinical stage II unresectable melanoma with BRAF mutation, was initiated on treatement with Dabrafenib and Trametinib. He complained of generalised edema and increased his weight by 27 kg. This progressed to shortness of breath and he underwent echocardiogram which revealed cardiac tamponade.

Diagnoses

Emerg

SUBMITTER: Sundaram VR 

PROVIDER: S-EPMC6221704 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature